Oncosil Medical Ltd
OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC).
The business
OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.
Small Caps Research
No research on Oncosil Medical Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise OSL based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Weekly wrap: six days of gains as rate cuts outlook improves
Expectations of central bank interest rate cuts drove global markets higher, carrying the Australian market up for its sixth straight day of gains. Stronger than expected US retail spending prompted a solid day on Wall Street after retail sales data topped expectations and jobless applications were lower than expected. That strength carried over on to […]
OncoSil Medical sees 78% surge in brachytherapy device use for pancreatic cancer
OncoSil Medical (ASX: OSL) has announced a 78% increase in the number of doses of its OncoSil single-use brachytherapy device used in commercial treatments for patients with pancreatic cancer, reflecting a growing adoption of the device in clinical practice. The increase was recorded during the three months to the end of June and was 2.7 […]
OncoSil Medical obtains CE Mark and breakthrough device designation for its pancreatic tumour isotope
Medical device company OncoSil Medical (ASX: OSL) has announced that it has finally received the CE Mark from the British Standards Institute (BSI) for its proprietary OncoSil device – a means of treating locally advanced pancreatic cancer (LAPC) in combination with chemotherapy. The company said OncoSil is a first in class medical device comprising microparticles containing phosphorus-32, […]
FDA grants breakthrough device designation for OncoSil
Medical device company OncoSil Medical (ASX: OSL) has been granted what’s known as breakthrough device designation by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer in combination with systemic chemotherapy. OncoSil’s “first in class” medical device is comprised of microparticles containing phosphorus-32, a pure beta-emitter radioisotope that’s implanted directly into […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.